Scioto Biosciences

Recent Finacing

Equity

Recent Raise

$26.5M

Scioto Biosciences develops live bacterial therapeutics via its proprietary ABT platform, advancing SB‑121 for gut–brain disorders (ASD, NEC) and delivery‑enhanced microbiome applications in human and animal health.

Founded 2017

Indiana, United States

11-50

Private

sciotobiosciences.com

Highlights

Focus Areas

Biotechnology

Diabetes

Health Care

Life Science

Therapeutics

Recent Investors

Financials

$28.3M

Total Raised

2

Funding rounds

4

Investors

Team

Upgrade to view the team

See the team members at Scioto Biosciences.